Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 652
- Registration Number
- NCT00667251
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT00667862
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: LBH589 (i.v. panobinostat)
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00663832
- Locations
- 🇨🇦
Novartis Investigative Site, Hamilton, Ontario, Canada
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1285
- Registration Number
- NCT00662597
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Sinai Hospital of Baltimore - The Alvin & Lois Lapidus Cancer Institute, Baltimore, Maryland, United States
🇺🇸Arlington Cancer Center, Arlington, Texas, United States
A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00658333
- Locations
- 🇺🇸
Novarits, Fargo, North Dakota, United States
🇺🇸Novartis, Charlottesville, Virginia, United States
Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
- Conditions
- Metastatic Renal Cell Cancer
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00655252
- Locations
- 🇺🇸
The Cancer Institute, St. Joseph Medical Center, Towson, Maryland, United States
🇺🇸Indiana University Cancer center, Indianapolis, Indiana, United States
🇺🇸Cliveland Clinic Foundation, Cleveland, Ohio, United States
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT00654589
- Locations
- 🇩🇪
Novartis Investigative Site, Leipzig, Germany
A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT00651209
- Locations
- 🇹🇭
Novartis, Bangkok, Thailand
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT00644878
- Locations
- 🇺🇸
USC Norris Cancer Center Jane Anne Nohl, Los Angeles, California, United States
🇺🇸St. Agnes Hospital, Baltimore, Maryland, United States
🇺🇸South Texas Institute of Cancer, Corpus Christi, Texas, United States
Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00640588
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Spain